{"nctId":"NCT00596271","briefTitle":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIXÂ® 1440","startDateStruct":{"date":"2005-09"},"conditions":["Japanese Encephalitis"],"count":192,"armGroups":[{"label":"IC51 and Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51","Other: Placebo"]},{"label":"HAVRIX and placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: HAVRIX","Other: Placebo"]},{"label":"IC51 and HAVRIX","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51","Biological: HAVRIX"]}],"interventions":[{"name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]},{"name":"HAVRIX","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* In female subjects either childbearing potential terminated by surgery or one year post-menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the study period and 30 days after the last vaccination by practicing reliable methods of contraception\n* Written informed consent obtained prior to study entry\n\nExclusion Criteria:\n\n* History of clinical manifestation of any flavivirus infection\n* History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \\>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)\n* History of any previous Hepatitis A vaccination and infection\n* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine\n* Planned administration of another vaccine during the study period\n* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy\n* A family history of congenital or hereditary immunodeficiency\n* History of autoimmune disease\n* Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination.\n* Any acute infections within 4 weeks prior to enrollment\n* Infection with human immunodeficiency virus (HIV), Hepatitis B (HBsAg) or Hepatitis C","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) at Day 56 for Anti-JEV Neutralizing Antibodies","description":"anti-JEV Neutralizing Antibodies were tabulated for IC51 groups only; for HAV GMTs (co-primary endpoint GMT for Hepatitis A Virus (HAV) Antibody at Day 28), please refer to \"Outcome 2\" within outcome measure section","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192.2","spread":null},{"groupId":"OG001","value":"202.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate (SCR) at Day 56 for Plaque Reduction Neutralization Assay (PRNT) and HAV at Day 28","description":null,"classes":[]},{"type":"SECONDARY","title":"GMT and SCR for PRNT at Day 28 and HAV at Day 56","description":null,"classes":[]},{"type":"SECONDARY","title":"Safety","description":"Rate of Adverse Events (AEs), Serious Adverse Events (SAEs) and medically attended AEs, local and systemic tolerability, changes in safety laboratory parameters (hematology, serum chemistry, urinalysis)","classes":[]},{"type":"PRIMARY","title":"GMT for Hepatitis A Virus (HAV) Antibody at Day 28","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Headache","Nasopharyngitis","Fatique","Influenza like illness","Diarrhea"]}}}